Cadrenal Therapeutics (CVKD) Lytham Partners Fall 2024 Investor Conference summary

Company mission and drug development

• Focused on advancing tecarfarin, a next-generation blood thinner, to address the limitations of warfarin, which has been the sole vitamin K antagonist for decades.

• Tecarfarin was designed to overcome warfarin's unstable metabolism, which is affected by genetic variability and drug interactions, leading to severe adverse events.

Clinical trial insights and comparative data

• Tecarfarin demonstrated statistically significant superiority over warfarin in measured time in therapeutic range (TTR) in a head-to-head clinical trial, despite a study design that favored warfarin.

• Real-world TTR for warfarin averages 40-50%, while the trial's design artificially elevated warfarin's performance to 70% TTR.

• Imputation methods in the trial further inflated warfarin's results, but direct measurement still showed tecarfarin's advantage.

Recent clinical context and market opportunity

• Recent LVAD patient studies revealed suboptimal TTR and high hemorrhage rates with warfarin, highlighting the need for a better alternative.

• Tecarfarin is being positioned for pivotal studies in LVAD patients, a population with significant unmet need and high probability of regulatory success.

• The LVAD market includes 14-15,000 patients in the US and triple that worldwide, with growing implant rates.

• Success in LVADs could facilitate tecarfarin's adoption in other warfarin-dependent indications.